Skip to main content
Article thumbnail
Location of Repository

The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man

By Del Fiorentino Alessandra, Silvana Cianchetti, Alessandro Celi, Giulia Dell’Omo and Roberto Pedrinelli

Abstract

Anti-inflammatory properties may contribute to the pharmacological effects of angiotensin II receptor blockers (ARBs), a leading therapeutic class in the management of hypertension and related cardiovascular and renal diseases. That possibility, supported by consistent evidence from in-vitro and animal studies showing pro-inflammatory properties of angiotensin II, has been evaluated clinically by measuring the effect of ARBs on C-reactive protein and other circulating indices of inflammation (e-selectin, adhesion molecules, interleukin-6, tissue necrosis factor-alpha, monocyte chemoattractant protein-1) of potential clinical relevance, a body of evidence that this paper aims to review

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2672458
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. A memorial to Robert Tiegerstedt: the centennial of renin discovery.
    2. A; for the Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors.
    3. A; for the MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
    4. Additive benefi cial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients.
    5. Additive benefi cial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.
    6. an angiotensin type 1 receptor inhibitor, regulates markers of infl ammation in patients with premature atherosclerosis.
    7. an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease.
    8. and therapeutic differences among angiotensin II receptor antagonists.
    9. Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy. Diabetes Care.
    10. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinfl ammatory action.
    11. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol.
    12. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure.
    13. Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinfl ammatory cytokine release from leukocytes.
    14. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
    15. Angiotensin receptor blockade decreases markers of vascular infl ammation.
    16. Antioxidants block angiotensin II-induced increases in blood pressure and endothelin. Hypertension.
    17. Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease.
    18. Budaj A et al; for the ACTIVE Investigators. Rationale and design of ACTIVE: the atrial fi brillation clopidogrel trial with irbesartan for prevention of vascular events.
    19. (2006). C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev.
    20. (2005). C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med.
    21. (2004). C-reactive protein genotypes affect baseline, but not exercise training-induced changes, in C-reactive protein levels. Arterioscler Thromb Vasc Biol.
    22. C-reactive protein.
    23. (2003). Candesartan reduces oxidative stress and infl ammation in patients with essential hypertension. Hypertens Res.
    24. captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
    25. (1997). Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In
    26. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    27. Comparative effects of AT1-antagonism and angiotensin converting enzyme inhibition on markers of infl ammation and platelet aggregation in patients with coronary artery disease.
    28. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.
    29. (2008). Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res.
    30. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus.
    31. de Zeeuw D; for the RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    32. Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor.
    33. Effect of fl uvastatin and valsartan, alone and in combination, on postprandial vascular infl ammation and fi brinolytic activity in patients with essential hypertension.
    34. (2008). Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis. Int J Clin Pharmacol Ther.
    35. Effect of losartan in aging related endothelial impairment.
    36. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
    37. (2006). Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res.
    38. Effects of angiotensin II receptor blockade with valsartan on pro-infl ammatory cytokines in patients with essential hypertension.
    39. Effects of antihypertensive agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress.
    40. Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients.
    41. Effects of beta-blocker therapy on high sensitivity C-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure.
    42. Effects of combined candesartan and ACE inhibitors on BNP, markers of infl ammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
    43. (2002). Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1. Clin Sci.
    44. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and infl ammation and blood pressure (reninangiotensin system antagonists, oxidation, and infl ammation).
    45. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
    46. (2005). Effi cacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther.
    47. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction.
    48. Epidemiology, heritability, and genetic linkage of C-reactive protein in African Americans (from the Jackson Heart Study).
    49. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
    50. for the Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    51. for the DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.
    52. for the ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia.
    53. for the I-PRESERVE Investigators. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction.
    54. for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    55. for the Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.
    56. for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
    57. for the Losartan Heart Failure Survival Study ELITE II. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.
    58. for the Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial.
    59. for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
    60. H; for the EUropean Trial on Olmesartan and Pravastatin in Infl ammation and Atherosclerosis (EUTOPIA) Investigators. Antiinfl ammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinfl ammation.
    61. I; for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.
    62. (2008). Infl ammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem.
    63. (2000). International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev.
    64. Irbesartan signifi cantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina.
    65. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a metaanalysis.
    66. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profi le in a North of Sweden Effi cacy Evaluation (ALPINE study).
    67. Muiesan ML; for the CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators: Effects of candesartan cilexetil and enalapril on infl ammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
    68. NM; for the Microalbuminuria Reduction with Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus.
    69. Nuclear factor-kappaB: a pivotal transcription factor in chronic infl ammatory diseases.
    70. (2008). Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med.
    71. Physiology of local renin-angiotensin systems.
    72. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.
    73. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.
    74. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II.
    75. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
    76. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    77. Proinfl ammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade.
    78. ramipril, or both in patients at high risk for vascular events.
    79. (2000). Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept.
    80. Regular consumption of dark chocolate is associated with low serum concentrations of C-reactive protein in a healthy italian population.
    81. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/ dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]).
    82. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels.
    83. (2005). Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care.
    84. RL; for the PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events.
    85. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis.
    86. (2008). Role of the renin-angiotensin system in vascular infl ammation. Trends Pharmacol Sci.
    87. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction.
    88. S; for the VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    89. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial.
    90. (2003). Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost.
    91. (2006). Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res.
    92. Telmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytes.
    93. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease
    94. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade infl ammation in metabolic hypertensive patients.
    95. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects.
    96. The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients.
    97. Tognoni G; for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    98. Usefulness of quinapril and irbesartan to improve the anti-infl ammatory response of atorvastatin and aspirin in patients with coronary heart disease.
    99. VG; for the Val-HeFT Investigators. C-reactive protein in heart failure prognostic value and the effect of valsartan.
    100. WR; for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.